Discovery of the covalent SARS‐CoV‐2 M pro inhibitors from antiviral herbs via integrating target‐based high‐throughput screening and chemoproteomic approaches
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.29208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Ya-Ni Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Tradi…. Hauptthemen laut MEDLINE: COVID-19, Plants, Medicinal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
The main proteases (M pro ) are highly conserved cysteine‐rich proteins that can be covalently modified by numerous natural and synthetic compounds. Herein, we constructed an integrative approach to efficiently discover covalent inhibitors of M pro from complex herbal matrices. This work begins with biological screening of 60 clinically used antiviral herbal medicines, among which Lonicera japonica Flos (LJF) demonstrated the strongest anti‐M pro effect (IC 50 = 37.82 μg/mL). Mass spectrometry (MS)‐based chemical analysis and chemoproteomic profiling revealed that LJF extract contains at least 50 constituents, of which 22 exhibited the capability to covalently modify M pro . We subsequently verified the anti‐M pro effects of these covalent binders. Gallic acid and quercetin were found to potently inhibit severe acute respiratory syndrome coronavirus 2 M pro in dose‐ and time‐ dependent manners, with the IC 50 values below 10 µM. The inactivation kinetics, binding affinity and binding mode of gallic acid and quercetin were further characterized by fluorescence resonance energy transfer, surface plasmon resonance, and covalent docking simulations. Overall, this study established a practical approach for efficiently discovering the covalent inhibitors of M pro from herbal medicines by integrating target‐based high‐throughput screening and MS‐based assays, which would greatly facilitate the discovery of key antiviral constituents from medicinal plants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zitieren
APA
Zhang, Y. N., Zhu, G. H., Liu, W., Chen, X. X., Xie, Y. Y., Xu, J. R., Jiang, M. F., Zhuang, X. Y., Zhang, W. D., Chen, H. Z., & Ge, G. B. (2023). Discovery of the covalent SARS‐CoV‐2 M pro inhibitors from antiviral herbs via integrating target‐based high‐throughput screening and chemoproteomic approaches. Journal of Medical Virology. https://doi.org/10.1002/jmv.29208
Vancouver
Zhang YN, Zhu GH, Liu W, Chen XX, Xie YY, Xu JR, et al. Discovery of the covalent SARS‐CoV‐2 M pro inhibitors from antiviral herbs via integrating target‐based high‐throughput screening and chemoproteomic approaches. Journal of Medical Virology. 2023. doi:10.1002/jmv.29208
BibTeX
@article{Zhang2023,
author = {Zhang, Ya-Ni and Zhu, Guang-Hao and Liu, Wei and Chen, Xi-Xiang and Xie, Yuan-Yuan and Xu, Jian-Rong and Jiang, Mei-Fang and Zhuang, Xiao-Yu and Zhang, Wei-Dong and Chen, Hong-Zhuan and Ge, Guang-Bo},
title = {Discovery of the covalent SARS‐CoV‐2 M pro inhibitors from antiviral herbs via integrating target‐based high‐throughput screening and chemoproteomic approaches},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.29208}
}
EUVIMED